Hepatology Communications (Mar 2023)

Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study

  • Abdel Aziz Shaheen,
  • Gilaad G. Kaplan,
  • Keith A. Sharkey,
  • B. Cord Lethebe,
  • Mark G. Swain

DOI
https://doi.org/10.1097/HC9.0000000000000062
Journal volume & issue
Vol. 7, no. 3
pp. e0062 – e0062

Abstract

Read online

Background:. Depression is common in patients with chronic viral hepatitis. We evaluated the impact of major depressive disorder (MDD) and antidepressant use on survival among patients with HBV and HCV. Methods:. We used The Health Improvement Network database, the largest medical database in the UK, to identify incident HBV (n=1401) and HCV (n=1635) in patients between 1986 and 2017. Our primary composite outcome was the development of decompensated cirrhosis or death. MDD and each class of antidepressants were assessed in multivariate Cox proportional hazards models. Models were adjusted for age, sex, and clinical comorbidities. Results:. The prevalence of MDD among HCV patients was higher compared with HBV patients (23.5% vs. 9.0%, p0.001. MDD was not an independent predictor for decompensated cirrhosis-free survival or mortality. However, the use of tricyclic and tetracyclic antidepressants (TCAs) was associated with poor decompensated cirrhosis-free survival in HBV and HCV cohorts (adjusted HR: 1.80, 95% CI, 1.00–3.26 and 1.56, 95% CI, 1.13–2.14, respectively). Both TCAs in the HBV cohort and selective serotonin reuptake inhibitors among the HCV cohort were associated with poor overall survival (adjusted HR: 2.18, 95% CI, 1.16–4.10; 1.48, 95% CI, 1.02–2.16, respectively). Conclusions:. Although prevalent among viral hepatitis patients, MDD did not affect disease progression or survival in either HBV or HCV cohorts. TCA use was associated with poor decompensated cirrhosis-free survival. Therefore, its use should be further studied among viral hepatitis patients.